JP7774312B2 - 縮合環化合物、それらの製造方法、医薬組成物、およびそれらの使用 - Google Patents

縮合環化合物、それらの製造方法、医薬組成物、およびそれらの使用

Info

Publication number
JP7774312B2
JP7774312B2 JP2022569555A JP2022569555A JP7774312B2 JP 7774312 B2 JP7774312 B2 JP 7774312B2 JP 2022569555 A JP2022569555 A JP 2022569555A JP 2022569555 A JP2022569555 A JP 2022569555A JP 7774312 B2 JP7774312 B2 JP 7774312B2
Authority
JP
Japan
Prior art keywords
alkyl
group
halogenated
compound
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022569555A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023526791A (ja
JP2023526791A5 (https=
Inventor
ダイグオ ドン，
グァンポン チウ，
ヨンガン ワン，
ゾンロン レイ，
Original Assignee
クワンチョウ フェルミオン テクノロジー カンパニー リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by クワンチョウ フェルミオン テクノロジー カンパニー リミテッド filed Critical クワンチョウ フェルミオン テクノロジー カンパニー リミテッド
Publication of JP2023526791A publication Critical patent/JP2023526791A/ja
Publication of JP2023526791A5 publication Critical patent/JP2023526791A5/ja
Application granted granted Critical
Publication of JP7774312B2 publication Critical patent/JP7774312B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/52—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring condensed with a ring other than six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2022569555A 2020-05-21 2021-05-21 縮合環化合物、それらの製造方法、医薬組成物、およびそれらの使用 Active JP7774312B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN202010433988 2020-05-21
CN202010433988.6 2020-05-21
CN202110529033 2021-05-14
CN202110529033.5 2021-05-14
PCT/CN2021/095191 WO2021233427A1 (zh) 2020-05-21 2021-05-21 并环化合物及其制备方法、药物组合物和应用

Publications (3)

Publication Number Publication Date
JP2023526791A JP2023526791A (ja) 2023-06-23
JP2023526791A5 JP2023526791A5 (https=) 2024-05-23
JP7774312B2 true JP7774312B2 (ja) 2025-11-21

Family

ID=78672734

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022569555A Active JP7774312B2 (ja) 2020-05-21 2021-05-21 縮合環化合物、それらの製造方法、医薬組成物、およびそれらの使用

Country Status (8)

Country Link
US (1) US20230192683A1 (https=)
EP (1) EP4155305A4 (https=)
JP (1) JP7774312B2 (https=)
KR (1) KR20230015333A (https=)
CN (2) CN115991703A (https=)
AU (1) AU2021276301A1 (https=)
TW (1) TWI910166B (https=)
WO (1) WO2021233427A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI860849B (zh) 2021-09-14 2024-11-01 美商美國禮來大藥廠 Sstr4促效劑鹽
KR20240122964A (ko) 2023-02-06 2024-08-13 에이치엘만도 주식회사 피스톤 밸브 조립체 및 이를 구비한 쇼크 업소버
JP2026509366A (ja) 2023-03-10 2026-03-18 イーライ リリー アンド カンパニー Ｓｓｔｒ４アゴニスト及びその塩の調製のための方法
AU2024236692A1 (en) 2023-03-10 2025-10-16 Eli Lilly And Company Methods for the preparation and dose regimens for use of sstr4 agonists and salts thereof
WO2024245077A1 (zh) * 2023-05-29 2024-12-05 武汉熙瑞医药科技有限公司 3-氮杂-双环[3.1.0]己烷衍生物、其制备方法及其应用
WO2025096300A1 (en) 2023-10-30 2025-05-08 Eli Lilly And Company Novel methods for the preparation of 3-azabicylco[3.1,0]hexane-6-carboxamide derivatives
CN120965687A (zh) * 2024-05-17 2025-11-18 广州费米子科技有限责任公司 Sstr4激动剂类化合物的晶体形式及其制备方法和用途
WO2025247982A1 (en) 2024-05-29 2025-12-04 Grünenthal GmbH Piperazines which act as sstr4 modulators

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012125661A1 (en) 2011-03-17 2012-09-20 Merck Sharp & Dohme Corp. Substituted 3-azabicyclo[3.1.0]hexane derivatives useful as ccr2 antagonists
US20140343295A1 (en) 2013-05-15 2014-11-20 Korea Institute Of Science And Technology Novel 6-pyrazolylamido-3-substituted azabicyclo[3.1.0]hexane compounds as calcium channel inhibitors
WO2015037716A1 (ja) 2013-09-12 2015-03-19 住友化学株式会社 含窒素飽和複素環化合物
JP2016518430A (ja) 2013-05-17 2016-06-23 セントレクシオン セラピューティクス コーポレイション 新規ソマトスタチン受容体亜型４（ｓｓｔｒ４）作動薬

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105315293A (zh) * 2014-07-29 2016-02-10 上海科州药物研发有限公司 作为蛋白激酶抑制剂的杂环化合物及其制备方法和用途

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012125661A1 (en) 2011-03-17 2012-09-20 Merck Sharp & Dohme Corp. Substituted 3-azabicyclo[3.1.0]hexane derivatives useful as ccr2 antagonists
US20140343295A1 (en) 2013-05-15 2014-11-20 Korea Institute Of Science And Technology Novel 6-pyrazolylamido-3-substituted azabicyclo[3.1.0]hexane compounds as calcium channel inhibitors
JP2016518430A (ja) 2013-05-17 2016-06-23 セントレクシオン セラピューティクス コーポレイション 新規ソマトスタチン受容体亜型４（ｓｓｔｒ４）作動薬
WO2015037716A1 (ja) 2013-09-12 2015-03-19 住友化学株式会社 含窒素飽和複素環化合物

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ChemMedChem，2018年，13(10)，p.983-987
DATABASE REGISTRY [ONLINE] Retrieved from STN，検索日：12 MAR 2025, 掲載日：～２０２０年１月２日, RN 2398170-01-7 REGISTRY 等
野崎正勝 等，創薬化学，第１版，株式会社化学同人，1995年，p.98-99

Also Published As

Publication number Publication date
CN115991703A (zh) 2023-04-21
WO2021233427A1 (zh) 2021-11-25
US20230192683A1 (en) 2023-06-22
EP4155305A4 (en) 2024-07-10
TW202146402A (zh) 2021-12-16
TWI910166B (zh) 2026-01-01
EP4155305A1 (en) 2023-03-29
AU2021276301A1 (en) 2023-01-19
JP2023526791A (ja) 2023-06-23
CN113717167B (zh) 2022-12-02
CN113717167A (zh) 2021-11-30
KR20230015333A (ko) 2023-01-31

Similar Documents

Publication Publication Date Title
JP7774312B2 (ja) 縮合環化合物、それらの製造方法、医薬組成物、およびそれらの使用
CN113929693B (zh) 含氮杂环化合物、药物组合物和应用
EP4495113A1 (en) Kif18a inhibitor
TW202227397A (zh) 雙環的－雜環衍生物及相關用途
CA3133753A1 (en) Novel small molecule inhibitors of tead transcription factors
CN113717161B (zh) 含氮饱和杂环化合物及其制备方法、药物组合物和应用
CN118660887A (zh) 三环稠杂环类pde3/4双重抑制及其用途
TWI393708B (zh) 異羥肟酸脂化合物，其用途及其之合成方法
EP3375781A1 (en) Benzo ring derivative with b2 receptor agonist and m3 receptor antagonist activities and use thereof in medicine
CA3145344A1 (en) Pyrazolopyrimidine compound, preparation method for same and applications thereof
JP2025529613A (ja) 電位開口型ナトリウムチャネル阻害剤としての化合物
JP7814359B2 (ja) 受容体阻害剤、同阻害剤を含む医薬組成物及びその使用
CN117651703A (zh) 取代的氨基甲酸大环化合物及其相关治疗方法
CN114685520B (zh) 三并环化合物及其药物组合物和应用
CN118496202A (zh) 生长抑制素受体亚型4(sstr4)激动剂
CN119730843A (zh) 取代的吡咯烷基和哌啶基化合物以及相关的治疗方法
TWI916367B (zh) 含氮飽和雜環化合物及其製備方法、藥物組合物和應用
TR201908937T4 (tr) P38 MAP kinazı inhibe eden indanil üre bileşikleri.
CN116535424B (zh) 作为malt1抑制剂的三并环化合物及其药物组合物和应用
HK40062713B (en) Fused-ring compounds, preparation method, pharmaceutical composition and use thereof
HK40062713A (en) Fused-ring compounds, preparation method, pharmaceutical composition and use thereof
EP4620950A1 (en) Piperidine derivative, salt of same, and pharmaceutical composition containing same as active ingredient
TW202600134A (zh) 一種多元螺環化合物的鹽及其晶型、其製備方法和醫藥用途
HK40032239B (en) Receptor inhibitors, pharmaceutical compositions comprising the same and use thereof
TW202543599A (zh) 一種多元螺環化合物的晶型、其製備方法和醫藥用途

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240513

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240513

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20250325

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250401

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250623

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250916

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251002

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20251007

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20251104

R150 Certificate of patent or registration of utility model

Ref document number: 7774312

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150